The Same Molecule, Two Products
Semaglutide was first approved by the FDA in 2017 as Ozempic — a weekly injectable for type 2 diabetes management. In 2021, Novo Nordisk received a second approval for the same molecule at a higher dose, marketed as Wegovy, specifically for chronic weight management in adults with obesity or overweight with at least one weight-related condition.
The molecule is identical. What differs is the approved dose, the approved indication, and consequently, how insurance covers each product and which patients a physician can prescribe it to under standard FDA labeling.
| Factor | Ozempic | Wegovy |
|---|---|---|
| Active Ingredient | Semaglutide | Semaglutide |
| FDA Indication | Type 2 diabetes | Chronic weight management |
| Max Approved Dose | 2 mg weekly | 2.4 mg weekly |
| Insurance Coverage | Often covered for T2D | Rarely covered |
| Brand List Price | ~$900/month | ~$1,350/month |
| Compounded Alternative | Yes (same molecule) | Yes (same molecule) |
Why Ozempic Became a Weight Loss Drug Anyway
Ozempic was approved for diabetes, but physicians quickly observed — and trials confirmed — that its weight loss effects were profound in patients without diabetes as well. Off-label prescribing of Ozempic for weight loss became common. This is legal: physicians can prescribe any approved medication off-label at their clinical discretion. Wegovy was then approved to give semaglutide an on-label weight management indication and allow higher dosing.
The practical result is that many patients who cannot access Wegovy through insurance use Ozempic off-label instead — at lower doses. Those seeking the full 2.4 mg therapeutic weight loss dose without brand-name pricing increasingly turn to compounded semaglutide through telehealth platforms and 503B pharmacy partners.
"The molecule is not the barrier. The pricing and insurance architecture around it is. Compounded semaglutide exists because a $1,300/month medication is simply inaccessible for most people — regardless of clinical need."
Where Compounded Semaglutide Fits
Compounded semaglutide uses the identical active molecule as both Ozempic and Wegovy, produced in an FDA-regulated 503B outsourcing facility under cGMP conditions. It is not a generic — generics do not exist for semaglutide. It is a compounded version of the same drug, made to order under clinical supervision.
The clinical mechanism is the same. The sourcing at a 503B facility is regulated. The prescribing requires a licensed provider. The access cost is dramatically lower than brand-name alternatives. For patients who are clinically appropriate candidates for semaglutide therapy, compounded access through a legitimate telehealth provider is a viable and medically supervised option.
503B compounded semaglutide.
Physician-supervised. All 50 states.
Which One Should You Consider?
If you have type 2 diabetes and your insurance covers Ozempic, the brand-name product through your physician is a reasonable path. If you are seeking weight loss and do not have a diabetes diagnosis — or your insurance does not cover Wegovy — compounded semaglutide through a telehealth provider gives you the same clinical molecule at a fraction of the cost, with the same requirement for physician oversight and prescription.
The brand name is not what makes the therapy work. The molecule, the dose, the titration protocol, and the clinical oversight are what determine outcomes.